Helen Sabzevari Precigen, Inc. (PGEN) insider trading activity

Helen Sabzevari is President and CEO of PRECIGEN, INC.. Currently has a direct ownership of 2.76 Million shares of PGEN, which is worth approximately $4.22 Million. The most recent transaction as insider was on Jan 29, 2025, when has been sold 286,967 shares (Common Stock) at a price of $1.3 per share, resulting in proceeds of $373,057. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.76M

24.22% 3M change

76.87% 12M change

Total Value Held $4.22 Million

Helen Sabzevari Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 29 2025	SELL Payment of exercise price or tax liability	$373,057 $1.3 p/Share	286,967 Reduced 9.42%	2,759,109 Common Stock
Jan 29 2025	BUY Grant, award, or other acquisition	-	825,000 Added 21.31%	3,046,076 Common Stock
Apr 05 2024	SELL Payment of exercise price or tax liability	$574,499 $1.4 p/Share	410,357 Reduced 15.59%	2,221,076 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	1,071,429 Added 28.94%	2,631,433 Common Stock
Aug 25 2023	SELL Open market or private sale	$117,762 $1.53 p/Share	76,969 Reduced 4.7%	1,560,004 Common Stock
Aug 23 2023	BUY Exercise of conversion of derivative security	-	141,587 Added 7.96%	1,636,973 Common Stock
Aug 18 2023	SELL Open market or private sale	$92,719 $1.66 p/Share	55,855 Reduced 3.6%	1,495,386 Common Stock
Aug 16 2023	BUY Exercise of conversion of derivative security	-	141,587 Added 8.36%	1,551,241 Common Stock
Aug 11 2023	SELL Open market or private sale	$59,667 $1.44 p/Share	41,436 Reduced 2.86%	1,409,654 Common Stock
Aug 09 2023	BUY Exercise of conversion of derivative security	-	141,587 Added 8.89%	1,451,090 Common Stock
Aug 04 2023	SELL Open market or private sale	$58,157 $1.1 p/Share	52,870 Reduced 3.88%	1,309,503 Common Stock
Aug 02 2023	BUY Exercise of conversion of derivative security	-	141,587 Added 9.41%	1,362,373 Common Stock
Mar 24 2023	BUY Exercise of conversion of derivative security	-	283,173 Added 18.83%	1,220,786 Common Stock
Jan 27 2023	BUY Open market or private purchase	$39,999 $1.75 p/Share	22,857 Added 2.38%	937,613 Common Stock
Jan 04 2023	BUY Exercise of conversion of derivative security	-	17,665 Added 1.89%	914,756 Common Stock
May 13 2022	SELL Open market or private sale	$211,782 $1.19 p/Share	177,968 Reduced 16.55%	897,091 Common Stock
May 12 2022	BUY Exercise of conversion of derivative security	-	340,909 Added 24.08%	1,075,059 Common Stock
Jan 05 2022	SELL Open market or private sale	$24,986 $3.59 p/Share	6,960 Reduced 0.94%	734,150 Common Stock
Jan 04 2022	BUY Exercise of conversion of derivative security	-	17,667 Added 2.33%	741,110 Common Stock
Jan 03 2022	SELL Open market or private sale	$14,122 $3.67 p/Share	3,848 Reduced 0.53%	723,443 Common Stock
Jan 02 2022	BUY Exercise of conversion of derivative security	-	9,765 Added 1.32%	727,291 Common Stock
Jul 19 2021	SELL Open market or private sale	$68,043 $5.43 p/Share	12,531 Reduced 1.72%	717,526 Common Stock
Jul 17 2021	BUY Exercise of conversion of derivative security	-	25,000 Added 3.31%	730,057 Common Stock
May 13 2021	SELL Open market or private sale	$303,571 $6.4 p/Share	47,433 Reduced 6.3%	705,057 Common Stock
May 12 2021	BUY Exercise of conversion of derivative security	-	97,276 Added 11.45%	752,490 Common Stock

Also insider at

KNTE

Kinnate Biopharma Inc. Healthcare

Helen Sabzevari

President and CEO

Germantown, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PGEN shares.

Notify only if

Value

Insider Trading

Get notified when an Precigen, Inc. insider buys or sells PGEN shares.

Notify only if

Operation

Value

Type

News

Receive news related to PRECIGEN, INC.

Track Activities on PGEN

Account